Annual Meeting Session Handouts

Welcome to the 2012 AIPLA Annual Meeting session handouts page. Papers are available to all registered attendees. If a speaker has submitted material, there will be a link(s) to their bio, paper, and slides next to their name.

A DVD with all the submitted session materials will be sent to all registrants about 6 weeks after the conference. We will also have audio available online about 4 weeks after the meeting.

To access the session handouts, please Sign-In by clicking "Sign In" in the upper right corner of this web page. If you are having any trouble accessing the session handouts, please send us an email or call 703.415.0780.

Committee Meetings 6:30 – 8:00 am

Commitee meetings are open to all attendees unless otherwise noted.

Opening Plenary Session 8:00 – 9:00 am

AIPLA Year-in-Review and the Impact of the AIA Rules

Marriott Ballroom Salons 2 & 3, Lobby Level

Join AIPLA President Bill Barber, Officer-in-Charge, Sharon Israel, and Executive Director Q. Todd Dickinson, for a lively look at AIPLA’s accomplishments this past, year. In addition, the Honorable David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the US Patent & Trademark Office, will provide comments on the new AIA rules and will participate in an interview with Dickinson. Hear about these new rules and how they will impact your business and the IP world.

Biotechnology/Chemical Practice ( Joint Session)

(120 Minutes of CLE Requested)

IP Issues in Novel Venture Financing of Biopharmaceutical Development Funding is tight and risk is high in development of newdrugs and diagnostics. Creative financing and partnering structures are allowing companies to access funding to run clinical trials and generate new IP. The objective of the session is to describe the novel arrangements and IP issues that patent attorneys need to know.

Mergers and Acquisitions

(120 Minutes of CLE Requested)

IP People v. Corporate People - Why Can’t We Be Friends!? What Makes the Best Corporate/IP Partnership in M&A Transactions?

In a merger and acquisition deal, it is important for both sides, corporate and IP, to understand the other and to understand the elements that go into making a deal flow as efficiently and effectively as possible, while not sacrificing quality. This discussion is intended to give insight into ways to work together to get the deal done!

Patent Law

(60 Minutes of CLE Requested)

Thurgood Marshall Ballroom, Mezzanine Level

Moderator: Paul Kitch, Nixon Peabody, LLP, Chicago, IL

Declarations and Assignments and Effective Filing Date of Claims Under the AIA

We will delve into the details of the AIA rules associated with Declarations and Assignments and how these rules enable Assignee-as-applicant filings. We will also examine the intricacies of handling an application that would appear to have an effective filing date of pre-AIA implementation but, due to later added claims, may get swept into the category of an application subject to the new AIA rules and prior art definitions because it contains or ever contained a claim not entitled to a filing date before March 16, 2013.

Lunch Reception (open to all registrants)

11:45 am – 12:15 pm

Exhibition Hall A, Exhibition Level

Luncheon 12:15 – 1:45 pm

Concurrent Afternoon Tracks 2:00 – 3:30 pm

Track1: AIA—Will the New System Work?

Thurgood Marshall Ballroom, Mezzanine Level

Moderator: Q. Todd Dickinson, AIPLA, Arlington, VA

AIPLA Executive Director Q. Todd Dickinson will lead a frank and informative question and answer session with notable government, private practice, and industry IP stakeholders. The discussion will center around the expectations and early results from the various changes to the patent system implemented by the America Invents Act.

Panelists:

Honorable David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the US Patent & Trademark Office, Alexandria, VA (invited) (Bio, Slides)

Antibody Patents and Patenting Antibodies—US and EP Perspectives Patenting Antibodies—A European Perspective The EP panel will explain and critique the EPO’s approach to inventive step and claim scope for antibodies.

A Corporate View

An Industry View

Licensing and Management of IP Assets (120 Minutes of CLE Requested)

Maryland Ballroom, Lobby Level

Moderator: Penny Prater, Chevron, San Ramon, CA

The doctrine of licensing estoppel affects all technological disciplines of Patent Law. The Rates v. Speakeasy decision by the Second Circuit Court of Appeals held that patent licensing agreements reached before litigation cannot be used to bar a licensee from later challenging the validity of a patent. David Leichtman, counsel for Speakeasy, Inc. and Best Buy Co., Inc. will speak on the doctrine of licensing estoppel and the affects of the decision.